key: cord-0915554-q64zo60m
authors: Tromp, Katja; van der Zee, Philip; Rokx, Casper; van Kampen, Jeroen; Gommers, Diederik; Endeman, Henrik
title: Effect of Methylprednisolone on Inflammation and Coagulation in Patients with Severe COVID-19: A Retrospective Cohort Study
date: 2021-06-04
journal: Biomark Insights
DOI: 10.1177/11772719211021647
sha: 57176cb4c8787eeb1c160f4c4bab6de3a3445b23
doc_id: 915554
cord_uid: q64zo60m

Corticosteroids reduced mortality rate in patients with coronavirus disease 2019 (COVID-19). Previously, we hypothesized that corticosteroids mitigate the inflammation response resulting in reduced coagulation and thrombosis. In this retrospective study, we included 27 patients with COVID-19 that received high-dose corticosteroids (methylprednisolone 1000 mg i.v. daily for 3 days) for persistent respiratory failure or an excessive inflammation response. We found that inflammation, coagulation, and ventilation parameters improved significantly after methylprednisolone. The viral loads of SARS-CoV-2 remained stable or decreased. These results provides insight into the reduced mortality rate observed in patients with COVID-19 treated with corticosteroids.

. Inflammation, coagulation, and ventilation parameters after start of methylprednisolone. We observed a significant increase in PaO 2 /FiO 2 ratio and a decrease in positive end-expiratory pressure (PEEP) from Day 3 up to Day 14. At Day 7, peak pressure was reduced and respiratory system compliance improved significantly.

The viral loads of SARS-CoV-2 generally remained stable or decreased after methylprednisolone. We observed 8 blood stream infections per 1000 catheter days, which was above the norm in our general ICU population of 3 infections per 1000 catheter days. One case of ventilator-associated pneumonia was observed. All infections occurred in different patients.

In this study, we showed that corticosteroids reduced inflammation and coagulation parameters after a median of 13 days of mechanical ventilation in patients with COVID-19. These data suggest that methylprednisolone is associated with reduced hypercoagulation, although it remains unclear whether corticosteroids reduce hypercoagulation directly, indirectly through reducing inflammatory mediators, or both. In accordance with previous research, this study suggests that high-dose corticosteroids did not result in increased replication of SARS-CoV-2 in a relatively late stage of COVID-19. 5 Despite the small sample size, lack of control group, and the relatively late stage of COVID-19, this study showed that inflammation, coagulation, and ventilation parameters improved in patients with COVID-19 and provides us with greater insight into the reduced mortality rate observed in patients with COVID-19 treated with corticosteroids.

Dexamethasone in hospitalized patients with Covid-19-preliminary report

Progressive respiratory failure in COVID-19: a hypothesis

COVID-19: consider cytokine storm syndromes and immunosuppression

Decontamination of the digestive tract and oropharynx in ICU patients

Glucocorticoid therapy does not delay viral clearance in COVID-19 patients

Conception of the work: KT, PZ, HE Data acquisition and analysis: KT, PZ Drafting the manuscript: KT, PZ Revising the manuscript: CR, JK, DG, HE Final approval of the version: KT, PZ, CR, JK, DG, HE All authors had full access to all the data and take responsibility for the integrity of the data and accuracy of data analysis

The medical ethical board of the Erasmus MC Rotterdam approved this study (MEC-2020-0381) and a waiver of informed consent was given. All procedures followed were in accordance with the Helsinki Declaration of 1975, as revised in 2000.

Katja Tromp https://orcid.org/0000-0002-8790-9115 Philip van der Zee https://orcid.org/0000-0002-5577-6848

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.